The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 237 of the 241 references it cites were found in a registry or an index.
Abstract
Objective: To develop clinical practice guidelines for the management of patients with primary aldosteronism. Participants: The Task Force included a chair, selected by the Clinical Guidelines Subcommittee of the Endocrine Society, six additional experts, a methodologist, and a medical writer. The guideline was cosponsored by American Heart Association, American Association of Endocrine Surgeons, European Society of Endocrinology, European Society of Hypertension, International Association of Endocrine Surgeons, International Society of Endocrinology, International Society of Hypertension, Japan Endocrine Society, and The Japanese Society of Hypertension. The Task Force received no corporate funding or remuneration. Evidence: We searched for systematic reviews and primary studies to formulate the key treatment and prevention recommendations. We used the Grading of Recommendations, Assessment, Development, and Evaluation group criteria to describe both the quality of evidence and the strength of recommendations. We used “recommend” for strong recommendations and “suggest” for weak recommendations. Consensus Process: We achieved consensus by collecting the best available evidence and conducting one group meeting, several conference calls, and multiple e-mail communications. With the help of a medical writer, the Endocrine Society's Clinical Guidelines Subcommittee, Clinical Affairs Core Committee, and Council successfully reviewed the drafts prepared by the Task Force. We placed the version approved by the Clinical Guidelines Subcommittee and Clinical Affairs Core Committee on the Endocrine Society's website for comments by members. At each stage of review, the Task Force received written comments and incorporated necessary changes. Conclusions: For high-risk groups of hypertensive patients and those with hypokalemia, we recommend case detection of primary aldosteronism by determining the aldosterone-renin ratio under standard conditions and recommend that a commonly used confirmatory test should confirm/exclude the condition. We recommend that all patients with primary aldosteronism undergo adrenal computed tomography as the initial study in subtype testing and to exclude adrenocortical carcinoma. We recommend that an experienced radiologist should establish/exclude unilateral primary aldosteronism using bilateral adrenal venous sampling, and if confirmed, this should optimally be treated by laparoscopic adrenalectomy. We recommend that patients with bilateral adrenal hyperplasia or those unsuitable for surgery should be treated primarily with a mineralocorticoid receptor antagonist.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Algorithm for the detection, confirmation, subtype testing, and treatment of PA. a We recommend unilateral laparoscopic adrenalectomy for patients with documented unilateral PA (ie, APA or UAH) (1 ⎪ QQQE ). If a patient is unable or unwilling to undergo surgery, we recommend medical treatment including a MR antagonist (1 ⎪ QQQE ). If an ARR-positive patient is unwilling or unable to undergo further investigations, we similarly recommend medical treatment including an MR antagonist (1 ⎪ QQEE ). b Instead of proceeding directly to subtype classification, we recommend that patients with a positive ARR undergo one or more confirmatory tests to definitively confirm or exclude the diagnosis (1 ⎪ QQEE ). However, in the setting of spontaneous hypokalemia, undetectable renin, and PAC > 20 ng/dL (550 pmol/L), we suggest that there may be no need for further confirmatory testing (2 ⎪ QEEE ). c We recommend that when surgical treatment is feasible and desired by the patient, an experienced radiologist should use AVS to make the distinction between unilateral and bilateral adrenal disease (1 ⎪ QQQE ). Younger patients ( < age 35) with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions with radiological features consistent with a cortical adenoma on adrenal CT scan may not need AVS before proceeding to unilateral adrenalectomy (2 ⎪ QEEE ). [Adapted from J. W. Funder et al: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab . 2008;93:3266-3281 (3), with permission. © Endocrine Society.]](https://figures.cochat.ai/paper-figures/aaade82f5c4b425bbdee69e74321806d/the-management-of-primary-aldosteronism-case-detection-diagnosis-and-treatment-figure-1.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The most common types of secondary hypertension in adults are renal parenchymal disease, renovascular hypertension, primary aldosteronism, chronic sleep apnea, and substance/drug-induced.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A specific cause of secondary hypertension can be identified in 5%-10% of hypertensive patients (Table 11).”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Early diagnosis of secondary hypertension and the institution of appropriate targeted treatment have the potential to cure hypertension in some patients or improve BP control/reduce the number of prescribed antihypertensive medications in others.”
From 2020 International Society of Hypertension Global Hypertension Practice Guidelines (2020) · cites this paper as [116]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Hypokalemia, which reduces aldosterone secretion, should be corrected with oral K+ supplements before testing.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients with unilateral disease (50%; aldosterone-producing adenoma or, much less frequently, unilateral hyperplasia) respond to unilateral laparoscopic adrenalectomy with complete cure (≈50%) or improvement (≈50%) in BP control.”
From Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association (2018) · cites this paper as [289]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht151 · Cited by 13,655
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“The Task Force followed the approach recommended by the Grading of Recommendations, Assessment, Development, and Evaluation group, an international group with expertise in the development and implementation of evidence-based guidelines (2).”
MethodNational High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents (2004) · PEDIATRICS · doi:10.1542/peds.114.2.s2.555 · Cited by 6,938
Mancia, G., Fagard, R., Narkiewicz, K., Redón, J., Zanchetti, A., Böhm, M., Christiaens, T., Cifkova, R., De Backer, G., Dominiczak, A., et al. (2013) · Journal of Hypertension · doi:10.1097/01.hjh.0000431740.32696.cc · Cited by 5,655
Pitt, B., Remme, W., Zannad, F., Neaton, J., Martinez, F., Roniker, B., Bittman, R., Hurley, S., Kleiman, J., & Gatlin, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030207 · Cited by 4,941
(1997) · Archives of Internal Medicine · doi:10.1001/archinte.1997.00440420033005 · Cited by 3,777
(2003) · Journal of Hypertension · doi:10.1097/00004872-200311000-00002 · Cited by 2,672
Funder, J. W., Carey, R. M., Fardella, C., Gomez-Sanchez, C. E., Mantero, F., Stowasser, M., Young, W. F., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0104 · Cited by 1,554 · cited 3×
“The recommendations and suggestions made by the Task Force were subject to extensive consultation before being published in the Journal of Clinical Endocrinology and Metabolism in 2008 (3).”
MethodSelf-citationEvidence for an increased rate of cardiovascular events in patients with primary aldosteronism
Milliez, P., Girerd, X., Plouin, P.-F., Blacher, J., Safar, M. E., & Mourad, J.-J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.01.015 · Cited by 1,547 · cited 2×
“Several outcome studies also have provided evidence that PA patients are particularly at risk of cardiovascular/ renal complications, including arrhythmias, myocardial infarction, strokes, chronic kidney disease, and death, compared with age-, sex-, and BP-matched essential hypertensives (30, 33, 156).”
BackgroundResultA prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467 · cited 2×
“However, some groups have suggested that when clinicians administer a bolus injection of cosyntropin and sample the adrenal veins simultaneously, cosyntropin does not improve the diagnostic accuracy of AVS, and, in fact, cosyntropin may increase secretion from the nonadenomatous gland to a greater degree than from the…”
BackgroundSelf-citation
Research works printed but not linked: 3
- 15. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertensioninadultsattheMayoClinicfrom1973through1975. Mayo Clin Proc . 1977;52:549-545.
- 133. FardellaCE,PintoM,MossoL,Gómez-SánchezC,JalilJ,Montero J. Genetic study of patients with dexamethasone-suppressible aldosteronismwithoutthechimericCYP11B1/CYP11B2gene. J Clin Endocrinol Metab . 2001;86:4805-4807.
- 169. Jacobsen NE, Campbell JB, Hobart MG. Laparoscopic versus openadrenalectomyforsurgicaladrenaldisease. CanJUrol . 2003; 10:1995-1999.
Cited by
Items 601–700 of 1,002
Genetic Alterations in Benign Adrenal Tumors
Pitsava, G., & Stratakis, C. A. (2022) · Biomedicines · doi:10.3390/biomedicines10051041 · Cited by 25
Yamashita, T. S., Shariq, O. A., Foster, T. R., Lyden, M. L., Dy, B. M., Young, W. F., Bancos, I., & McKenzie, T. J. (2022) · World Journal of Surgery · doi:10.1007/s00268-022-06780-x · Cited by 22
“This dichotomy in treatment approach stems from the longstanding dogma that UA in the setting of bilateral PA is non-curative and results in a suboptimal BP response [6, 10].”
BackgroundSelf-citationDiscordance and shortcomings of aldosterone suppression tests in primary aldosteronism
Tsai, C., Salle, S. P., Brown, J. M., Newman, A. J., Chang, C., Wu, V., Lin, Y., & Vaidya, A. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf170 · Cited by 21
Holler, F., Heinrich, D. A., Adolf, C., Lechner, B., Bidlingmaier, M., Eisenhofer, G., Williams, T. A., & Reincke, M. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0985-0 · Cited by 23
Self-citationManosroi, W., Atthakomol, P., Phinyo, P., & Inthaphan, P. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.925591 · Cited by 24
Utsumi, T., Iijima, S., Sugizaki, Y., Mori, T., Somoto, T., Kato, S., Oka, R., Endo, T., Kamiya, N., & Suzuki, H. (2023) · International Journal of Urology · doi:10.1111/iju.15218 · Cited by 23
Zhou, Y., Wang, X., Hou, J., Wan, J., Yang, Y., Liu, S., Luo, T., Liu, Q., Xue, Q., & Wang, P. (2023) · Hypertension Research · doi:10.1038/s41440-023-01420-w · Cited by 23
“Then, saline-loading test was performed to con fi rm the diagnosis of primary aldosteronism when plasma aldosterone level was greater than 10 ng/dL after saline infusion [8].”
InfluentialMortality in Patients With Primary Aldosteronism: A Swedish Nationwide Study
Gkaniatsa, E., Sandström, T. Z., Rosengren, A., Trimpou, P., Olsson, D. S., Lind, M., Muth, A., Johannsson, G., & Ragnarsson, Ó. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21895 · Cited by 23
Gupta, G., Teo, A. E. D., Swee, D. S., Loh, L. M., Chuah, M. B., Loh, W. J., Saffari, S. E., Koh, X. H., Kek, P. C., & Puar, T. H. K. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad752 · Cited by 22
Castro, M. A., Ruiz-Sánchez, J. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Aguilera-Saborido, A., Cerezo, J. F. G., Lazareno, N. L., Quesada, M. E. T., Ramos, J. G., Oriola, J., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03751-1 · Cited by 25
Primary Aldosteronism: Diagnosis and Management
Gyamlani, G. G., Headley, C. M., Naseer, A., Valaulikar, G., & Geraci, S. A. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.06.015 · Cited by 22
“Magnetic resonance imaging has no advantage over CT in localization, as it is more expensive and has less spatial resolution.(22) Presently, AVS is considered essential to direct therapy for patients with primary PA.”
BackgroundMethodInfluentialAn Individualized Approach to The Evaluation and Management of Primary Aldosteronism
Vaidya, A., Malchoff, C. D., & Auchus, R. J. (2017) · Endocrine Practice · doi:10.4158/ep161717.ra · Cited by 21
The aldosterone to renin ratio in the diagnosis of primary aldosteronism: Promises and challenges
O’Shea, P. M., Griffin, T. P., Denieffe, S., & Fitzgibbon, M. C. (2019) · International Journal of Clinical Practice · doi:10.1111/ijcp.13353 · Cited by 24
Resistant Hypertension Updated Guidelines
Chernova, I., & Krishnan, N. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1209-6 · Cited by 23
Clinical characterization of patients with primary aldosteronism plus subclinical Cushing’s syndrome
Yasuda, S., Hikima, Y., Kabeya, Y., Iida, S., Oikawa, Y., Isshiki, M., Inoue, I., Shimada, A., & Noda, M. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-0490-0 · Cited by 23
Torresan, F., Rossitto, G., Bisogni, V., Lerco, S., Maiolino, G., Cesari, M., Zhu, R., Iacobone, M., Seccia, T. M., & Rossi, G. P. (2020) · Clinical Science · doi:10.1042/cs20200340 · Cited by 23
Dominguez, D. A., Chatani, P. D., Murphy, R., Copeland, A. R., Chang, R., Sadowski, S. M., Hannah‐Shmouni, F., Stratakis, C. A., & Nilubol, N. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09692-7 · Cited by 21
“Here we demonstrate that, after adjusting for chemical and biochemical factors in the multivariable model, only ARS was independently associated with a ccHTN following unilateral adrenalectomy in patients with PA.”
BackgroundMethodInfluentialA Clinical Challenge: Endocrine and Imaging Investigations of Adrenal Masses
Sundin, A., Hindié, E., Avram, A. M., Tabarin, A., Pacák, K., & Taïeb, D. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.246066 · Cited by 22
Adrenal Venous Sampling for Subtype Diagnosis of Primary Hyperaldosteronism
Naruse, M., Tanabe, A., Yamamoto, K. I., Rakugi, H., Kometani, M., Yoneda, T., Kobayashi, H. H., Abe, M., Ohno, Y., Inagaki, N., et al. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.1192 · Cited by 22
“Patients aged <35 years with spontaneous hypokalemia, marked aldosterone excess, and unilateral adrenal lesions on adrenal CT scan may not need AVS before unilateral adrenalectomy [3].”
BackgroundInfluentialFlammia, R. S., Anceschi, U., Tufano, A., Bologna, E., Proietti, F., Bove, A. M., Misuraca, L., Mastroianni, R., Tirone, G., Carrara, A., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11051263 · Cited by 22
“Clinical subtypes of PHA include unilateral, aldosterone producing adenoma (uPHA), unilateral adrenal hyperplasia (uAH), and bilateral adrenal hyperplasia (bAH) [7].”
BackgroundInfluentialPathogenesis of Primary Aldosteronism: Impact on Clinical Outcome
de Santana, L. S., Guimaraes, A. G., & Almeida, M. Q. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.927669 · Cited by 22
Spyroglou, A., Handgriff, L., Müller, L., Schwarzlmueller, P., Parasiliti‐Caprino, M., Fuß, C. T., Remde, H., Hirsch, A., O’Toole, S. M., Thuzar, M., et al. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0040 · Cited by 23
Self-citationGuagliardo, N. A., Yao, J., Stipes, E. J., Cechova, S., Le, T. H., Bayliss, D. A., Breault, D. T., & Barrett, P. Q. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.11962 · Cited by 21
Insulin sensitivity and pancreatic β-cell function in patients with primary aldosteronism
Grewal, S., Fosam, A., Chalk, L., Deven, A., Suzuki, M., Correa, R. R., Blau, J. E., Demidowich, A. P., Stratakis, C. A., & Muniyappa, R. (2021) · Endocrine · doi:10.1007/s12020-020-02576-y · Cited by 20
“PA workup was performed in accordance with guidelines [27], which included measurement of plasma aldosterone and renin, a saline suppression test, adrenal venous sampling, and computerized tomography (CT) imaging.”
MethodWu, M.-H., Liu, F.-H., Lin, K.-J., Sun, J.-H., & Chen, S.-T. (2019) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000000987 · Cited by 20
the Chongqing Primary Aldosteronism Study (CONPASS) Group, Zhang, Y., Tan, J., Yang, Q. Z., Du, Z., Yang, S., He, W., Song, Y., Hu, J., Yang, Y., et al. (2020) · Journal of Medical Case Reports · doi:10.1186/s13256-020-2353-8 · Cited by 20
Diagnostic value of parameters from a spot urine sample for renal potassium loss in hypokalemia
Li, J., Ma, H., Lei, Y., & Wan, Q. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.10.024 · Cited by 21
External Validation of Clinical Prediction Models in Unilateral Primary Aldosteronism
Sam, D., Kline, G. A., So, B., Hundemer, G. L., Pasieka, J. L., Harvey, A. M., Chin, A., Przybojewski, S. J., Caughlin, C. E., & Leung, A. A. C. (2021) · American Journal of Hypertension · doi:10.1093/ajh/hpab195 · Cited by 20
Bai, W., Yao, C., Mao, D., Wu, J., Wang, K., Wei, H., Huang, Z., Shi, Q., & Wang, N. (2022) · Journal of Healthcare Engineering · doi:10.1155/2022/3139929 · Cited by 22
Manosroi, W., Phudphong, P., Atthakomol, P., & Phimphilai, M. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-01135-y · Cited by 21
“; and 3) use of appropriate methods recommended by standard guidelines for diagnosing and confirming PA [2].”
BackgroundMethodArterial hypertension and chronic kidney disease: consensus statement on patient management
Chazova, I. E., Кislyak, O. A., Podzolkov, V. I., Bragina, A. E., Анатольевна, С. О., Solntseva, T. D., Elfimova, E. M., Солтановна, В. З., Fomin, V. V., & Mironova, O. I. (2023) · Systemic Hypertension · doi:10.38109/2075-082x-2023-1-5-19 · Cited by 25
Rossi, G. P., Bagordo, D., Amar, L., Azizi, M., Riester, A., Reincke, M., Degenhart, C., Widimsky, J., Jr., Naruse, M., Deinum, J., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.21247 · Cited by 21
Self-citationYoshida, Y., Fujiwara, M., Kinoshita, M., Sada, K., Miyamoto, S., Ozeki, Y., Iwamoto, M., Mori, Y., Nagai, S., Matsuda, N., et al. (2023) · Hypertension Research · doi:10.1038/s41440-023-01412-w · Cited by 20
Self-citationLai, Z.-Q., Fu, Y., Liu, J.-W., Zhang, H., Zhang, H., Liang, N., & Dong, Y. (2023) · Hypertension Research · doi:10.1038/s41440-023-01503-8 · Cited by 20
“The most common sub-types of PA are idiopathic aldosteronism (IHA) and aldosterone adenoma (APA), with unilateral laparoscopic adrenalectomy being the suggested fi rst choice for APA patients and mineralocorticoid receptor antagonists (MRAs) being the recommended fi rst choice for IHA patients [5].”
InfluentialHealth Care Challenges in the Management of Primary Aldosteronism in Southeast Asia
Sukor, N., Sunthornyothin, S., Tran, T. V., Tarigan, T. J. E., MERCADO-ASIS, L. B., Satha, S., Aung, M. W., Yong, A. M. L., Minuljo, T. T., Villa, M. L., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae039 · Cited by 21
Zhang, X.-G., Song, Y., Jing, Y., Hu, J., Shen, H., Zhang, A., He, W., Feng, Z., Yang, Y., Pang, H., et al. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae747 · Cited by 22
Local origins impart conserved bone type-related differences in human osteoblast behaviour
M Shah, V. G., Shah, M., Gburcik, V., Reilly, P., Sankey, R. A., Emery, R. J., Clarkin, C., & Pitsillides, A. A. (2015) · European Cells and Materials · doi:10.22203/ecm.v029a12 · Cited by 20
Volumetric and densitometric evaluation of the adrenal glands in patients with primary aldosteronism
Degenhart, C., Schneller, J., Oßwald, A., Pallauf, A., Riester, A., Reiser, M. F., Reincke, M., & Beuschlein, F. (2016) · Clinical Endocrinology · doi:10.1111/cen.13258 · Cited by 21
Self-citationTeo, A. E. D., Garg, S., Johnson, T. I., Zhao, W., Zhou, J., Gómez-Sánchez, C. E., Gurnell, M., & Mj, B. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.09156 · Cited by 22
“Analogous negative feedback has been reported in ZG adjacent to APA, where both subtypes of 3β-hydroxysteroid dehydrogenase-isomerase (3β-HSD), responsible for synthesizing progesterone from pregnenolone, were found to be suppressed.36 Our results also showed that NPNT promotes adhesion in normal adrenal cells and in…”
BackgroundInfluentialHaase, M., Dringenberg, T., Allelein, S., Willenberg, H. S., & Schott, M. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-117179 · Cited by 20
“Calcium channel blockers (dihydropyridines) may increase renin levels while aldosterone levels will be unchanged or even lowered slightly [4].”
BackgroundDiagnosing endocrine hypertension: a practical approach
Yang, J., Shen, J., & Fuller, P. J. (2017) · Nephrology · doi:10.1111/nep.13078 · Cited by 22
“An argument could be made, however, for bypassing confirmatory testing in hypertensive patients with spontaneous hypokalaemia, very suppressed renin levels together with PAC > 550 pmol/L, who may be diagnosed as having PA without further evaluation because of the very low likelihood of having the disorder.(25) For oth…”
BackgroundVanderriele, P., Caroccia, B., Seccia, T. M., Piazza, M., Lenzini, L., Torresan, F., Iacobone, M., Unger, T., & Rossi, G. P. (2018) · Clinical Science · doi:10.1042/cs20171593 · Cited by 23
Impact of aldosterone-producing cell clusters on diagnostic discrepancies in primary aldosteronism
Kometani, M., Yoneda, T., Aono, D., Karashima, S., Demura, M., Nishimoto, K., Yamagishi, M., & Takeda, Y. (2018) · Oncotarget · doi:10.18632/oncotarget.25418 · Cited by 21
“, selectivity index > 2 for pre-ACTH AVS and > 5 for post-ACTH AVS [25]).”
BackgroundKishimoto, S., Oki, K., Maruhashi, T., Kajikawa, M., Matsui, S., Hashimoto, H., Takaeko, Y., Kihara, Y., Chayama, K., Goto, C., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001989 · Cited by 20
“Therapy for IHA in the form of administration of mineralocorticoid receptor antagonists (spironolactone and eplerenone) is well established [21,27].”
Wu, C., Wu, V., Yang, Y., Lin, Y., Yang, S., Lin, P., Chang, C., Tsai, Y., Wang, S., TAIPAI group, et al. (2019) · American Journal of Hypertension · doi:10.1093/ajh/hpz098 · Cited by 20
Ren, K., Jia, W. P., Liu, Q., Zhu, Y., Wu, N., Tang, Y., Li, Q., Zhang, Q., Yu, Y., An, Z., et al. (2019) · BMC Endocrine Disorders · doi:10.1186/s12902-019-0395-y · Cited by 20
Incidental Congestive Heart Failure in Patients With Aldosterone‐Producing Adenomas
Huang, W., Chen, Y., Lin, Y., Chen, L., Lin, P., Lin, Y., Liu, Y., Wu, C., Chueh, S., Chu, T., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012410 · Cited by 21
“Current Therapeutic Practice Among Patients With APA Although a significant number of patients with PA with APAs can be cured by surgical adrenalectomy, many patients are treated medically with an MRA.(37,38) The benefits of adrenalectomy on our patients are obvious and associated with a lower risk of CHF (sHR, 0.”
BackgroundMethodInfluentialImpact of cone beam - CT on adrenal vein sampling in primary aldosteronism
Meyrignac, O., Arcis, É., Delchier, M.-C., Mokrane, F., Darcourt, J., Rousseau, H., & Bouhanick, B. (2019) · European Journal of Radiology · doi:10.1016/j.ejrad.2019.108792 · Cited by 20
Old and new genes in primary aldosteronism
Boulkroun, S., Fernandes-Rosa, F. L., & Zennaro, M. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101375 · Cited by 21
Liu, Y., Zhou, L., Liu, Z., Ma, Y., Lin, L., Zhu, Y., Wang, K., & Li, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00023 · Cited by 28
The landscape of molecular mechanism for aldosterone production in aldosterone-producing adenoma
Oki, K., & Gómez-Sánchez, C. E. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0478 · Cited by 22
Barros, E., Rigalli, J. P., Tapia-Castillo, A., Vecchiola, A., Young, M. J., Hoenderop, J. G. J., Bindels, R. J. M., Fardella, C., & Carvajal, C. A. (2021) · Endocrinology · doi:10.1210/endocr/bqab032 · Cited by 22
Primary aldosteronism subtyping in the setting of partially successful adrenal vein sampling
Lee, S., Park, S. W., Choi, M. S., Kim, G., Yoo, J. H., Ahn, J., Jun, J. E., Park, H. S., Hyun, D., Cho, S. K., et al. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018821989239 · Cited by 20
Hemodynamic and Non-Hemodynamic Components of Cardiac Remodeling in Primary Aldosteronism
Pan, C., Wu, X.-M., Tsai, C., Chang, Y., Chen, Z., Chang, C., Lee, B., Liao, C., Chen, Y., Lin, L., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.646097 · Cited by 20
Non-Alcoholic Fatty Liver Disease and Hypokalemia in Primary Aldosteronism Among Chinese Population
Chen, Y., Chen, X., Chen, Q., & Yu, C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.565714 · Cited by 21
Wang, W., Wang, J., Shen, C., Zhu, S., Gao, Y., & Zhang, J. (2021) · BioMed Research International · doi:10.1155/2021/6635594 · Cited by 22
“Nonfunctional adrenal adenoma was diagnosed by functional assessment, excluding patients with CS [20], primary aldosteronism [21], pheochromocytoma [22], and infiltrative diseases such as adrenal lymphoma and metastatic carcinoma.”
MethodJędrusik, P., Symonides, B., Wojciechowska, E., Gryglas, A., & Gaciong, Z. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180117 · Cited by 22
Maruyama, K., Sofue, K., Okada, T., Koide, Y., Ueshima, E., Iguchi, G., Tani, R., Gentsu, T., Horinouchi, H., Sasaki, K., et al. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-2135-5 · Cited by 20
Management of posaconazole-induced pseudohyperaldosteronism
Davis, M. R., Nguyen, M.-V. H., Gintjee, T. J., Odermatt, A., Young, B. Y., & Thompson, G. R. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa366 · Cited by 20
ACE Inhibition to Distinguish Low-Renin Hypertension From Primary Aldosteronism
Tsai, C., Brown, J. M., Salle, S. P., Newman, A. J., Wu, V., Lin, Y., & Vaidya, A. (2025) · Hypertension · doi:10.1161/hypertensionaha.125.24711 · Cited by 19
“Endocrine Society criterion: a post-CCT PRA that remained <1 ng/mL per hour, in addition to a PAC that declined <30% of baseline, as recommended by the Endocrine Society clinical practice guideline 36 ; 2.”
Challenges and opportunities of wearable molecular sensors in endocrinology and metabolism
Güntner, A. T., Gerber, P. A., Dittrich, P. S., Serra, N., Figalli, A., Puhan, M. A., & Beuschlein, F. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01175-z · Cited by 26
“Likewise, challenges in the management of secondary hypertension are its non-specific presentation and the diversity of its causes, necessitating a comprehensive and costly diagnostic approach 106–108 .”
Wu, A., Wolley, M. J., Wu, Q., Gordon, R. D., Fenton, R. A., & Stowasser, M. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-00439-7 · Cited by 19
Self-citationTolerability and Efficacy of Long-Term Medical Therapy in Primary Aldosteronism
Tang, F., Loh, L. M., Foo, R., Loh, W. J., Lim, D. S. T., Zhang, M., Tan, P. T., Swee, D. S., Khoo, J. J. C., Tay, D., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab144 · Cited by 20
“As a result, the majority of patients with AVS-confirmed unilateral disease undergo surgery, precluding a direct comparison of surgical and medical therapy.”
BackgroundMethodInfluentialYuan, Y., Li, N., Liu, Y., Zhu, Q., Heizhati, M., Zhang, W., Yao, X., Zhang, D., Luo, Q., Wang, M., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.753074 · Cited by 21
Changes of the CYP11B2 Expressing Zona Glomerulosa in Human Adrenals From Birth to 40 Years of Age
van de Wiel, E. C. J., Baz, A. H. C., Küsters, B., Mukai, K., van Bonzel, L., van Erp, M., Deinum, J., & Langenhuijsen, J. F. (2022) · Hypertension · doi:10.1161/hypertensionaha.122.19052 · Cited by 19
Zuo, R. M., Liu, S., Li, W., Xia, Z., Xu, L., & Pang, H. (2024) · EJNMMI Research · doi:10.1186/s13550-024-01125-2 · Cited by 19
“All patients were diagnosed with PA by clinical endocrinologists following the guidelines of the Endocrine Society [5], and all participants completed the 1 mg dexamethasone inhibition test to determine whether they had complicated Cushing’s syndrome.”
BackgroundMethodPREVALENCE OF PRIMARY ALDOSTERONISM IN AN URBAN HYPERTENSIVE POPULATION
Galati, S.-J., Cheesman, K. C., Springer-Miller, R., Hopkins, S. M., Krakoff, L. R., Bagiella, E., Zhuk, R. A., Ying, T. K., Amer, C., Boyajian, M. K., et al. (2016) · Endocrine Practice · doi:10.4158/e161332.or · Cited by 19
Management of incidental adrenal tumours
Hanna, F., Issa, B. G., Sim, J., Keevil, B. G., & Fryer, A. A. (2018) · BMJ · doi:10.1136/bmj.j5674 · Cited by 20
Zhang, G., Zou, X., Liu, Q., Xie, T., Huang, R., Kang, H. Y., Lai, C., & Zhu, J. (2018) · International Journal of Experimental Pathology · doi:10.1111/iep.12267 · Cited by 21
Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism
Hashimura, H., Shen, J., Fuller, P. J., Chee, N. Y. N., Doery, J. C. G., Chong, W., Choy, K. W., Gwini, S. M., & Yang, J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13757 · Cited by 19
Heinrich, D. A., Adolf, C., Quinkler, M. O., Holler, F., Lechner, B., Nirschl, N., Sturm, L., Görge, V., Beuschlein, F., & Reincke, M. (2019) · European Journal of Endocrinology · doi:10.1530/eje-19-0138 · Cited by 21
Self-citationLin, L., Zhou, L., Guo, Y., Liu, Z., Chen, T., Liu, Z., Wang, K., Li, J., Zhu, Y., & Ren, Y. (2019) · Annales d Endocrinologie · doi:10.1016/j.ando.2019.10.001 · Cited by 22
Seated saline infusion test in predicting subtype diagnosis of primary aldosteronism
Kaneko, H., Umakoshi, H., Ishihara, Y., Sugawa, T., Nanba, K., Tsuiki, M., Kusakabe, T., Satoh‐Asahara, N., Yasoda, A., & Tagami, T. (2019) · Clinical Endocrinology · doi:10.1111/cen.14111 · Cited by 20
Loh, H. H., & Sukor, N. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-019-0294-8 · Cited by 21
Effects of Primary Aldosteronism and Different Therapeutic Modalities on Glucose Metabolism
Kwak, M. K., Lee, J. Y., Kim, B., Lee, S. H., & Koh, J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122194 · Cited by 20
“In patients with unsuccessful AVS according to the selectivity index (SI) or those with intermediate values in lateralization index (LI) of between three and four in AVS findings [34], we used other clinical, biochemical, AVS findings (such as contralateral ratio and ipsilateral ratio), and ability or willingness to u…”
BackgroundMethodResultInfluentialYatabe, M., Bokuda, K., Yamashita, K., Morimoto, S., Yatabe, J., Seki, Y., Watanabe, D., Morita, S., Sakai, S., & Ichihara, A. (2020) · Hypertension Research · doi:10.1038/s41440-020-0445-x · Cited by 19
Genetic screening for monogenic hypertension in hypertensive individuals in a clinical setting
Bao, M., Li, P., Li, Q., Chen, H., Zhong, Y., Li, S., Jin, L., Wang, W., Chen, Z., Zhong, J., et al. (2020) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2019-106145 · Cited by 20
Adolf, C., Braun, L., Fuß, C. T., Hahner, S., Kunzel, H. E., Handgriff, L., Sturm, L., Heinrich, D. A., Schneider, H., Bidlingmaier, M., et al. (2020) · Endocrine · doi:10.1007/s12020-020-02348-8 · Cited by 19
Self-citationDalmazi, G. D., Morandi, L., Rubin, B., Pilon, C., Asioli, S., Vicennati, V., Leo, A. D., Ambrosi, F., Santini, D., Pagotto, U., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa585 · Cited by 19
Adrenal vein sampling for primary aldosteronism: a 15-year national referral center experience
Kocjan, T., Jensterle, M., Vidmar, G., Vrckovnik, R., Berden, P., & Stankovič, M. (2020) · Radiology and Oncology · doi:10.2478/raon-2020-0052 · Cited by 20
Nonfunctional adrenal incidentalomas may be related to bisphenol-A
Eker, F., Güngüneş, A., Durmaz, Ş. A., Kısa, Ü., & Celik, Z. R. (2020) · Endocrine · doi:10.1007/s12020-020-02502-2 · Cited by 19
Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism
Tezuka, Y., & Turcu, A. F. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.625457 · Cited by 21
Wu, V.-C., Peng, K., Kuo, Y.-P., Liu, H., Tan, B. C.-M., Lin, Y.-H., Lai, T.-S., Chen, Y.-M., Chueh, J. S., & TAIPAI (2021) · Hypertension · doi:10.1161/hypertensionaha.121.18006 · Cited by 19
“†The LI was calculated as the ratio of the aldosterone/cortisol (A/C) concentration quotient on the dominant side over the A/C concentration quotient on the contralateral side.(1) CLS is calculated as nondominant adrenal (A/C ratio)/(IVC A/C ratio).”
MethodBenefits of Surgical Over Medical Treatment for Unilateral Primary Aldosteronism
Ahmed, S., & Hundemer, G. L. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.861581 · Cited by 22
CTNNB1Mutation in Aldosterone Producing Adenoma
Wang, J., Peng, K., Wu, V., Tseng, F., & Wu, K. (2017) · Endocrinology and Metabolism · doi:10.3803/enm.2017.32.3.332 · Cited by 20
Characteristics of adrenal incidentalomas in a New Zealand centre
Goh, Z., Phillips, I., Hunt, P. J., Soule, S. G., & Cawood, T. (2017) · Internal Medicine Journal · doi:10.1111/imj.13651 · Cited by 23
Nagasawa, M., Yamamoto, K. I., Rakugi, H., Takeda, M., Akasaka, H., Umakoshi, H., Tsuiki, M., Takeda, Y., Kurihara, I., Itoh, H., et al. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002047 · Cited by 20
“Nevertheless, these guidelines do not necessarily recommend to avoid adrenalectomy in all the patients with laterality index less than 4, as these patients, particularly who have laterality index close to 4, could have either unilateral or bilateral primary aldosteronism [1,9].”
BackgroundMethodSelf-citationGunnarsdóttir, H., Jónsdóttir, G., Birgisson, G., Gudmundsson, J., & Sigurjónsdóttir, H. Á. (2022) · Endocrine Research · doi:10.1080/07435800.2022.2068572 · Cited by 20
“Bilateral disease (BD) is treated with mineralocorticoid receptor antagonists (MRA).(14) Treatment appears to reduce cardiovascular and renal complications and long-term mortality to levels seen in patients with essential HT.”
BackgroundMethodInfluentialHigh body fat percentage is associated with primary aldosteronism: a cross-sectional study
Manosroi, W., & Atthakomol, P. (2020) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00654-w · Cited by 18
Huang, C., Huang, T., Yang, Y., Chang, L., Tu, Y., Wu, V., & Chen, J. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.038714 · Cited by 19
“34 The primary outcomes examined in the study was MACE, which comprised mainly the following: cardiovascular death, CAD, stroke, HF, and arrhythmia.”
Rossitto, G., Miotto, D., Battistel, M., Barbiero, G., Maiolino, G., Bisogni, V., Sanga, V., & Rossi, G. P. (2016) · Journal of Hypertension · doi:10.1097/hjh.0000000000001082 · Cited by 19
“5 cm and/or severe hypertension, considering the high likelihood of an APA [9,20], adrenalectomy was offered regardless of the AVS results because of the need to achieve blood pressure (BP) control with pharmacologic therapy [21].”
BackgroundMethodProspective Screening for Primary Aldosteronism in Patients With Suspected Obstructive Sleep Apnea
Chee, M. R., Hoo, J., Libianto, R., Gwini, S. M., Hamilton, G. S., Narayan, O. P., Young, M. J., Fuller, P. J., & Yang, J. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16902 · Cited by 18
He, K., Zhang, Z., Wang, Z., Wang, Y., Wang, Y., Zhang, H., Dong, Y., & Xiao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.634879 · Cited by 20
“Aldosteroneproducing adenoma (APA) is one of the most common types of PA and is mainly treated by surgical resection of lesions with excessive aldosterone secretion (10).”
BackgroundInfluentialWhole blood methylome-derived features to discriminate endocrine hypertension
Armignacco, R., Reel, P. S., Reel, S., Jouinot, A., Septier, A., Gaspar, C., Perlemoine, K., Larsen, C. K., Bouys, L., Braun, L., et al. (2022) · Clinical Epigenetics · doi:10.1186/s13148-022-01347-y · Cited by 18
Self-citationManosroi, W., Danpanichkul, P., & Atthakomol, P. (2022) · Scientific Reports · doi:10.1038/s41598-022-24280-9 · Cited by 18
Badran, M., Bender, S. B., & Gozal, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032245 · Cited by 19
“now recommends screening of PA among this group of patients [314].”
Rowe, N. E., Kumar, R., Schieda, N., Siddiqi, F. S., McGregor, T. B., McAlpine, K., Violette, P. D., Bathini, V., Eng, M. K., Izard, J., et al. (2023) · Canadian Urological Association Journal · doi:10.5489/cuaj.8248 · Cited by 21
Castro, M. A., Ruiz-Sánchez, J. G., Ramírez, P. A. P., Rojas‐Marcos, P. M., Aguilera-Saborido, A., Cerezo, J. F. G., Lazareno, N. L., Quesada, M. E. T., Ramos, J. G., Oriola, J., et al. (2024) · Endocrine · doi:10.1007/s12020-024-03773-9 · Cited by 20
“The initial dose can be between 50 – 100 mg twice a day [1] and the maximum established dose is 200 – 300 mg/24 h in divided doses [24].”
InfluentialFuld, S., Constantinescu, G. A., Pamporaki, C., Peitzsch, M., Schulze, M., Yang, J., Müller, L., Prejbisz, A., Januszewicz, A., Remde, H., et al. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfae017 · Cited by 19
Self-citationAdrenal Vein Sampling: Tips and Tricks
Kobayashi, K., Alkukhun, L., Rey, E., Salaskar, A. L., & Acharya, R. (2024) · Radiographics · doi:10.1148/rg.230115 · Cited by 19
Metadata
- Authors
- Funder, J. W., Carey, R. M., Mantero, F., Murad, M. H., Reincke, M., Shibata, H., Stowasser, M., & Young, W. F.
- Affiliations
- Hudson Institute of Medical Research (AU)
- University of Virginia Health System (US)
- University of Padua (IT)
- Mayo Clinic (US)
- Klinikum of the Ludwig-Maximilians-University of Munich (M.R.), 80366 München, Bavaria, Germany
- Oita University (JP)
- The University of Queensland (AU)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2016-05-01
- Volume
- 101
- Issue
- 5
- Pages
- 1889-1916
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2290633895
- Semantic Scholar
- 36716f26ebd3b8e468f352d9132208c41e5688c0
- Cited by
- 2,925
- References
- 241
- Citations by year
- 2026: 236 · 2025: 397 · 2024: 315 · 2023: 329 · 2022: 329 · 2021: 315 · 2020: 293 · 2019: 238 · 2018: 200 · 2017: 188 · 2016: 72
- FWCI
- 233.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- INFM-OAR (INFN Catania) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- primary aldosteronism, case finding, aldosterone-renin ratio, adrenal computed tomography, adrenal vein sampling, laparoscopic adrenalectomy, bilateral adrenal hyperplasia, mineralocorticoid receptor antagonists, hypertension, hypokalemia
- MeSH terms
- Adrenal Glands, Adrenalectomy, Aldosterone, Mineralocorticoid Receptor Antagonists, Humans, Hyperaldosteronism, Renin, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.